In a 23-year-old patient with multiple tubular adenomas, what is the next appropriate step in management?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 30, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Management of Multiple Tubular Adenomas in a 23-Year-Old

This patient requires germline genetic testing for APC and MUTYH genes immediately, as multiple colorectal adenomas (≥10) at this young age strongly suggests an underlying hereditary polyposis syndrome. 1

Immediate Next Steps

The presence of multiple tubular adenomas in a 23-year-old is highly abnormal and warrants urgent evaluation for hereditary colorectal cancer syndromes. The ASCO/ESMO guidelines explicitly state that patients with multiple colorectal adenomas (≥10) should be considered for germline genetic testing of APC and/or MUTYH 1. This young age of presentation makes hereditary polyposis syndromes—particularly attenuated familial adenomatous polyposis (AFAP) or MUTYH-associated polyposis (MAP)—the primary diagnostic considerations.

Genetic Testing Protocol

For APC testing:

  • Full germline genetic testing should include DNA sequencing AND large rearrangement analysis 1
  • This evaluates for both classic FAP and AFAP

For MUTYH testing:

  • In white populations, screening can begin with the most common mutations (G396D, Y179C) followed by full gene analysis in heterozygotes 1
  • For non-white individuals, proceed directly to full MUTYH sequencing 1
  • Consider ethnic-specific founder mutations 1

Surveillance While Awaiting Genetic Results

Given the patient's age and polyp burden, initiate colonoscopy surveillance every 1-2 years immediately 2. The British Society of Gastroenterology guidelines recommend annual colonoscopy for patients with 10 or more adenomas without identified constitutional pathogenic variants 2.

Critical Considerations by Syndrome

If AFAP is confirmed (APC mutation):

  • Continue colonoscopy every 1-2 years starting from diagnosis 1
  • Some patients can be managed conservatively with colonoscopy and polypectomy rather than immediate surgery 1
  • Surgery is indicated only if there are large numbers of adenomas or adenomas with high-grade dysplasia 1
  • Begin gastroduodenal surveillance at age 25-30 years 1

If MAP is confirmed (biallelic MUTYH mutations):

  • Annual colonoscopy is required 2
  • Begin gastroduodenal endoscopy at age 35 years 2
  • Surveillance protocol mirrors AFAP management 1

If no mutation is identified:

  • Continue annual colonoscopy surveillance 2
  • The patient falls into the "multiple colorectal adenomas" (MCRA) category
  • Maintain 1-2 yearly surveillance until age 75 2

Common Pitfalls to Avoid

  1. Do not delay genetic testing: The young age makes this almost certainly hereditary, and genetic diagnosis will guide both the patient's management and family screening

  2. Do not assume classic FAP: At age 23 with "multiple" (rather than hundreds of) adenomas, AFAP or MAP are more likely than classic FAP, which typically presents with hundreds to thousands of polyps by the teenage years

  3. Do not rush to surgery: Unlike classic FAP where prophylactic colectomy is often indicated, AFAP and MAP can frequently be managed endoscopically with intensive surveillance and polypectomy 1

  4. Do not forget family implications: Once a germline mutation is identified, first-degree relatives require genetic counseling and testing

Additional Screening Considerations

Once colorectal polyposis is confirmed or at age 25-30 years (whichever comes first), consider screening for extracolonic manifestations 1:

  • Gastroduodenal polyposis surveillance
  • Thyroid cancer screening (annual cervical ultrasound may be considered starting age 25-30) 1
  • Desmoid tumor screening if family history present 1

The molecular evidence suggests that even tubular adenomas with minor villous changes (1-20% villosity) carry increased malignant potential 3, reinforcing the need for aggressive surveillance in this young patient with multiple lesions.

References

Related Questions

When should a colonoscopy be repeated for a patient with a tubular adenoma, considering size (<10 mm vs ≥10 mm), number (single vs multiple), and histology (low‑grade dysplasia vs villous features)?
For a 38‑year‑old patient with a 1.2 cm tubular adenoma, what is the appropriate timing for the next colonoscopy?
How should a rectal lesion be managed when biopsy shows only a tubulovillous adenoma but MRI indicates extension into the internal sphincter and abutment of the external sphincter?
How does a tubulovillous adenoma differ from a tubular adenoma in terms of histology, size, malignancy risk, surveillance interval, and resection technique?
What is the appropriate management and surveillance interval for a tubular adenoma with low‑grade dysplasia detected on colonoscopy?
What is the appropriate management for a patient with serum iron of 37 µg/dL and ferritin of 34 ng/mL?
In a patient with chronic dysphagia and nausea refractory to ondansetron 8 mg every 6 hours and experiencing post‑prandial nausea and promethazine‑induced fatigue, what additional medications can be used to treat her symptoms while awaiting specialist evaluation?
In an adult kidney‑transplant recipient receiving standard immunosuppression (tacrolimus or cyclosporine, mycophenolate, prednisone), how should Journavx (suzetrigine) be dosed, monitored, and adjusted for renal impairment, and what alternative analgesics are recommended if severe renal dysfunction precludes its use?
Does ivermectin interact with ribociclib?
For what indications is magnesium sulfate used in pregnancy?
Do antidepressants suppress REM sleep or preserve it?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.